Posted by Adam Awdish on
Jiashu Xie, Zhengqiang Wang
Acta Pharmaceutica Sinica B
March 5, 2021
To date, the only FDA-approved drug for treating COVID-19 is Remdesivir (RDV), which can only be administered intravenously. RDV is a ProTide drug derived from nucleoside GS-441524, and the potency of RDV is dependent on intracellular conversion into GS-441524 triphosphate.
In vitro studies of RDV in human liver cells showed low stability on its own, indicating poor potential for oral use. However, it was observed that the stability levels were boosted when in the presence of cobicistat. Further, in vivo studies in human and mouse plasma showed promising levels of conversion to GS-441524 triphosphate when administered orally, indicating that RDV could potentially be taken as an oral drug.
Related products available from Innovative Research also include: